NUZ 6.25% 22.5¢ neurizon therapeutics limited

Ann: Results show MPL suppresses biomarkers associated with MND, page-200

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 2,739 Posts.
    lightbulb Created with Sketch. 1499
    Peeteepoo, my only thought on this is...how do you best determine the optimum phase 2 dose without these markers for each dose?

    I guess you could base it on adverse effects only, so go to highest dose that shows no adverse effects. But this doesnt seem optimal.

    Surely to give a potential phase 2 the best shot they'll take these samples across all dosing regimes? But possibly they won't publish them to the mushrooms.
 
watchlist Created with Sketch. Add NUZ (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.